PR
ORIC icon

PSP Research’s Oric Pharmaceuticals ORIC Stock Holding History

PSP Research’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$141K Hold
13,000
– – 0.07% 74
2026
Q1 		$165K Buy
+13,000
New +$148K 0.12% 74

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PSP Research's ORIC Position: Q2 2026 in Review

PSP Research held its Oric Pharmaceuticals (ORIC) position steady in Q2 2026 at 13,000 shares worth $141K. The position accounts for 0.07% of the portfolio, ranked #74.

PSP Research first reported a position in ORIC in Q1 2026 and has held it in 2 quarters since. The position peaked at $165K in Q1 2026. 180 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • PSP Research held 13,000 shares of Oric Pharmaceuticals worth $141K as of Q2 2026.
  • PSP Research left its Oric Pharmaceuticals share count unchanged in Q2 2026.
  • Oric Pharmaceuticals made up 0.07% of PSP Research's portfolio in Q2 2026, its #74 holding.
  • PSP Research first reported a position in Oric Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • PSP Research's Oric Pharmaceuticals position peaked at $165K in Q1 2026.
  • 180 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on PSP Research's 13F filing for Q2 2026, filed 9 Jul 2026.